OK, so earlier this week we learned the details of the $PAR cap raising:

• $14m via 73.7m shares at $0.19
• An SPP target raising $2.0m at $0.19 or a 2.5% discount to the VWAP during 5 days before the SPP close.

Each share has 1 attaching option at $0.2375 expiring at the earlier of 1/12/26 or 20 busines days after the release of the Interim Analysis (IA).

Each option, if exercised, then has a "piggy-back" option of $0.38, expiring in 30 April 2029.

The company says the raising was "significantly upsized' from the initial target of $8.0m due to "strong investor demand".

I've trawled through the release to try and understand why the change of strategy, as previously, it was clear they would await the IA - due in August (now maybe September) before raising. That's because a positive IA would be a potentially very significant SP catalyst given the market potential for an approved OA treatment.

I think part of the clue for the raising is in the bit I wrote above that the IA was due in August,... now maybe in September. With a quarterly cash burn of $11m and only $11m in the bank, things are getting tight, raising the reliance on the Obsidian convertible facility. More on that below.

Now $PAR does not explicitly state that it had changed its strategy, but the language in the announcement makes the rationale clear.

The company emphasised that the raising would “extend runway through the interim analysis and into the post-interim period,” rather than simply funding up to that milestone. This indicates a shift from the earlier approach of waiting for the interim results before raising capital, to ensuring the business is fully funded across that key inflection point and into the next stage, including NDA preparation. Management now seem to be prioritising certainty of funding over trying to time the market around the interim readout - but in truth they don't explain what is driving the change of heart.

A second factor highlighted was balance sheet flexibility. The company noted that part of the proceeds would be used to repay its Obsidian convertible note facility and “reduce reliance on future drawdowns.” This suggests the raise was partly motivated by a desire to avoid depending on potentially more expensive or restrictive funding sources if conditions deteriorate or if the interim result is less favourable than expected. By raising equity now, Paradigm strengthens its financial position ahead of a high-risk period. (Still that doesn't explain the change of position).

Finally, the structure of the deal shows an attempt to retain upside if the interim analysis is positive. The attaching options are explicitly designed to “accelerate additional capital inflows in the event of a positive clinical outcome.” Combined with the comment that the raise provides “funding flexibility through the upcoming interim analysis,” this indicates a more balanced strategy: secure funding upfront, reduce risk, and still leave room to raise further capital on better terms if the data is strong.

I think it is important to remember just how expensive the converitble debt facility is to $PAR. And as the SP of $PAR has fallen the terms of the facility which seek to protect the lender, become more onerous and likely more dilutive to $PAR shareholders.

So, it seems likely that the capital raising, the partial paydown of Obsidian, and the desire to be less reliant on Obsidian is in the best interests of shareholders.

To recap, here's where we are at:

Pre-raise: ~470–480m shares

Post-placement: ~545–555m shares

Post-SPP: ~555–565m shares

Fully diluted (incl. options): ~620–640m shares

So, it is a significant but not disastrous dilution.

And what does it buy? Well the latest OpCF burn was $11m for the quarter. So, at that rate, the raising buys 4-5 months space, with the options to likely buy another 5-6 months on top of that, and the "piggy back" options up to another 6-8 months.

So the raise + options + "piggy back" options is potentially enough to get through to an NDA decision, and therefore provides greater clarity of funding. Of course, that's provided the path to the NDA is straighforward and all options are exercised. Any delays in the process, and it won't be enough from my quick assessment.

Investment Decision

I have added to my small "research position" to a small 0.6% holding at $0.173 this morning, and will mull over whether to take this up to 1% by participating in the SPP.

Looking back at the earlier CT data, it is tempting to think this one has a good chance. However, the results were under-powered and can easily go either way in a controlled Phase 3 trial. So, this remains very much a binary bet. However, it is one I am prepared to place a small stake on.

Disc: Held